Please login to the form below

Not currently logged in

Akinion appoints Dr Richard Jones as CEO

He joins the biotech firm from GlaxoSmithKline

Akinion Dr Richard JonesDr Richard Jones has been appointed as chief executive officer for privately-held Swedish biotech firm Akinion Pharmaceuticals.

He brings more than 20 years of pharmaceutical industry experience to the company and arrives from Novartis where he was vice president, medicines commercialisation leader, haematology, global oncology.

Before that Dr Jones served at GlaxoSmithKline, where he was most recently VP, global haematology medicines commercialisation leader.

In that role he was responsible for delivering the big pharma company's global haematology strategy, and prior to he served at Sanofi Genzyme as director and M&A transition lead for its transplant and oncology global business unit.

In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently in a phase I/II clinical trial.

27th January 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....